

# Oliver Zivanovic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7805871/publications.pdf>

Version: 2024-02-01

97  
papers

2,947  
citations

172207

29  
h-index

182168

51  
g-index

99  
all docs

99  
docs citations

99  
times ranked

4069  
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. <i>Cell</i> , 2017, 170, 927-938.e20.	13.5	368
2	The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. <i>Gynecologic Oncology</i> , 2008, 111, 431-437.	0.6	153
3	A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. <i>Cancer</i> , 2012, 118, 660-669.	2.0	126
4	Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. <i>Journal of Clinical Oncology</i> , 2009, 27, 2066-2072.	0.8	119
5	The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2008, 108, 287-292.	0.6	109
6	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 140, 436-442.	0.6	97
7	A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 27-31.	0.6	95
8	Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. <i>Annals of Surgical Oncology</i> , 2016, 23, 196-202.	0.7	86
9	HIPEC ROC I: A phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2015, 136, 699-708.	2.3	75
10	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 246-251.	0.6	71
11	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. <i>Annals of Surgical Oncology</i> , 2016, 23, 2522-2528.	0.7	69
12	Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?. <i>Gynecologic Oncology</i> , 2018, 151, 24-31.	0.6	64
13	The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. <i>Gynecologic Oncology</i> , 2010, 116, 351-357.	0.6	61
14	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3324-3330.	0.8	61
15	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. <i>Gynecologic Oncology</i> , 2020, 156, 147-153.	0.6	61
16	Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 25-30.	0.6	59
17	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017, 145, 15-20.	0.6	55
18	Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. <i>Gynecologic Oncology</i> , 2020, 156, 591-597.	0.6	54

#	ARTICLE	IF	CITATIONS
19	Is It Time to Centralize Ovarian Cancer Care in the United States?. <i>Annals of Surgical Oncology</i> , 2016, 23, 989-993.	0.7	44
20	Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2192-2198.	0.7	43
21	A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 230-235.	0.6	43
22	Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 262-266.	0.6	43
23	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. <i>Gynecologic Oncology</i> , 2016, 142, 217-224.	0.6	42
24	Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. <i>International Journal of Hyperthermia</i> , 2017, 33, 548-553.	1.1	41
25	Treatment patterns of FIGO Stage IB2 cervical cancer: A single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. <i>Gynecologic Oncology</i> , 2008, 111, 265-270.	0.6	36
26	Sentinel Lymph Node Biopsy in the Management of Vulvar Carcinoma, Cervical Cancer, and Endometrial Cancer. <i>Oncologist</i> , 2009, 14, 695-705.	1.9	36
27	Advanced cytoreductive surgery: American perspective. <i>Gynecologic Oncology</i> , 2009, 114, S3-S9.	0.6	36
28	Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. <i>Gynecologic Oncology</i> , 2017, 146, 263-267.	0.6	33
29	Risk-reducing salpingectomy: Let us be opportunistic. <i>Cancer</i> , 2017, 123, 1714-1720.	2.0	31
30	Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. <i>Gynecologic Oncology</i> , 2017, 147, 115-119.	0.6	31
31	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. <i>Gynecologic Oncology</i> , 2018, 150, 44-49.	0.6	30
32	It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 555-561.	0.6	29
33	Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1915-1921.	1.2	29
34	Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 115, 209-214.	0.6	27
35	Evolution and outcomes of sentinel lymph node mapping in vulvar cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 383-386.	1.2	25
36	Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. <i>Gynecologic Oncology</i> , 2019, 154, 77-82.	0.6	24

#	ARTICLE	IF	CITATIONS
37	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. <i>Gynecologic Oncology</i> , 2019, 154, 144-149.	0.6	24
38	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. <i>Gynecologic Oncology</i> , 2020, 158, 608-613.	0.6	23
39	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e17.	1.0	22
40	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 122-129.	0.6	21
41	Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. <i>Cancer Medicine</i> , 2018, 7, 2280-2287.	1.3	21
42	Early diagnosis of genital mucosal melanoma: how good are our dermoscopic criteria?. <i>Dermatology Practical and Conceptual</i> , 2016, 6, 43-46.	0.5	21
43	Risk factors for financial toxicity in patients with gynecologic cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 817.e1-817.e9.	0.7	20
44	IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 670-683.	1.2	18
45	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2021, 163, 36-40.	0.6	18
46	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 447-456.	1.1	16
47	A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 433-437.	0.6	16
48	Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	0.6	16
49	Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3772-3780.	0.7	16
50	Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 299-302.	0.6	14
51	Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. <i>Gynecologic Oncology</i> , 2019, 154, 333-337.	0.6	14
52	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 687-692.	0.6	14
53	Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 143, 496-503.	0.6	12
54	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. <i>Gynecologic Oncology</i> , 2020, 159, 66-71.	0.6	12

#	ARTICLE	IF	CITATIONS
55	Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study. <i>Gynecologic Oncology</i> , 2020, 159, 187-194.	0.6	12
56	Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithm. <i>Gynecologic Oncology</i> , 2021, 162, 262-267.	0.6	12
57	Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 505-515.	0.6	11
58	Retroperitoneal lymph node dissection (RPLND). <i>Gynecologic Oncology</i> , 2008, 111, S66-S69.	0.6	10
59	A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 468-472.	0.6	10
60	Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 140, 383-386.	0.6	10
61	The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. <i>Gynecologic Oncology</i> , 2021, 160, 99-105.	0.6	10
62	Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100926.	0.3	10
63	Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 159-164.	1.2	10
64	Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program. <i>JAMA Oncology</i> , 2019, 5, 570.	3.4	9
65	Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. <i>Gynecologic Oncology</i> , 2021, 160, 438-444.	0.6	9
66	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. <i>Gynecologic Oncology</i> , 2022, 165, 239-247.	0.6	9
67	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. <i>Gynecologic Oncology</i> , 2021, 162, 345-352.	0.6	8
68	Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 371-374.	0.6	7
69	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	7
70	Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1377-1380.	1.2	7
71	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2020, 158, 397-401.	0.6	7
72	Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1189-1202.	2.0	7

#	ARTICLE	IF	CITATIONS
73	Why was GOG-0213 a negative trial?. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e19.	1.0	7
74	Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1554-1561.	1.2	7
75	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1162-1168.	1.2	6
76	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2022-003430.	1.2	5
77	Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after secondâ€look assessment. <i>Cancer</i> , 2008, 112, 2690-2697.	2.0	4
78	Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S137-S143.	0.6	4
79	Digital Technical and Informal Resources of Breast Cancer Patients From 2012 to 2020: Questionnaire-Based Longitudinal Trend Study. <i>JMIR Cancer</i> , 2021, 7, e20964.	0.9	4
80	Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1183-1188.	1.2	4
81	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 11-16.	0.5	3
82	Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. <i>Gynecologic Oncology</i> , 2016, 142, 13-18.	0.6	2
83	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>Gynecologic Oncology</i> , 2021, 160, 51-55.	0.6	2
84	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. <i>Gynecologic Oncology</i> , 2021, 160, 696-703.	0.6	2
85	Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 222-231.	1.2	2
86	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100154.	1.0	2
87	Surgical resection and reconstruction for advanced and recurrent gynecologic malignancies. <i>Expert Review of Obstetrics and Gynecology</i> , 2008, 3, 677-690.	0.4	1
88	Quaternary and beyond cytoreduction: An updated and expanded analysis. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100851.	0.3	1
89	Stage IA2 cervical cancer: Long-term outcomes with less radical as opposed to more radical surgical management.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17011-e17011.	0.8	1
90	Assessment of wound perfusion with near-infrared angiography: A prospective feasibility study. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100940.	0.3	1

#	ARTICLE	IF	CITATIONS
91	TabPRO trial: Tablet-based real-time detection of patient-reported outcomes during adjuvant outpatient chemotherapy for breast cancer.. Journal of Clinical Oncology, 2015, 33, TPS9640-TPS9640.	0.8	0
92	Neoadjuvant chemotherapy (NACT) selection for advanced stage ovarian cancer (AOC) at a comprehensive cancer center.. Journal of Clinical Oncology, 2015, 33, e16579-e16579.	0.8	0
93	Fertility-sparing surgery in stage IA2 cervical cancer: Associated factors and long-term survival.. Journal of Clinical Oncology, 2016, 34, e17012-e17012.	0.8	0
94	Long-term oncologic outcomes of fertility-sparing surgery in young women with stage IB1 cervical cancer.. Journal of Clinical Oncology, 2016, 34, e17010-e17010.	0.8	0
95	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival.. Journal of Clinical Oncology, 2016, 34, 5525-5525.	0.8	0
96	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. JCSM Clinical Reports, 2021, 6, 11-16.	0.5	0
97	Updates to the Literature on Anastomotic Leaks After Rectosigmoid Resection for Gynecologic Malignancies. Annals of Surgical Oncology, 2022, , .	0.7	0